Search for a command to run...
Natco Pharma Ltd. stands out as a strong growth performer in the Pharmaceuticals & Drugs sector, demonstrating exceptional revenue growth and profitability metrics. Its low valuation ratios further position it as an attractive investment opportunity compared to peers, who show varying levels of performance across profitability, growth, and valuation metrics.
Stocks | CMP | Market Cap | P/E | ROCE (%) | Debt/Equity |
---|---|---|---|---|---|
NATCOPHARM | ₹864.80 | ₹15,489.43Cr | 8.37 | 32.85% | 0.04 |
SUNPHARMA | ₹1,563.35 | ₹3,75,099.26Cr | 87.59 | 17.60% | 0.04 |
DIVISLAB | ₹6,091.05 | ₹1,61,698.50Cr | 73.20 | 16.46% | - |
CIPLA | ₹1,587.60 | ₹1,28,217.27Cr | 23.73 | 22.77% | 0.01 |
TORNTPHARM | ₹3,581.55 | ₹1,21,215.77Cr | 61.53 | 24.28% | 0.57 |
DRREDDY | ₹1,280.30 | ₹1,06,835.27Cr | 15.50 | 26.86% | 0.07 |
MANKIND | ₹2,518.95 | ₹1,03,926.59Cr | 55.18 | 28.38% | 0.02 |